account_balance
Investment manager · 13F filer · SEC CIK 1512848
NEA Management Company, LLC
Reported value$1.59Bas of Jun 30, 2026
Positions26 1 new, 1 sold out
Top 10 weight89.8%TRVI alone is 16%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
TRVITrevi Therapeutics, Inc.
15.5%
MBXMBX Biosciences, Inc.
12.6%
GLUEMonte Rosa Therapeutics, Inc.
11.7%
CELCCelcuity Inc.
11.3%Trimmed −25%
SGPSpyglass Pharma, Inc.
10.4%
SVRASavara, Inc.
9.5%
ZBIOZenas BioPharma, Inc.
6.4%
COURCoursera, Inc.
4.6%
AUPHAurinia Pharmaceuticals, Inc.
4.2%
CRSPCrispr Therapeutics AG
3.6%
ORICORIC Pharmaceuticals, Inc.
2.8%
PHAT1.3%TRVITrevi Therapeutics, Inc.
15.5%
MBXMBX Biosciences, Inc.
12.6%
GLUE11.7%CELC11.3%SGP10.4%SVRA9.5%ZBIO6.4%COUR4.6%AUPH4.2%CRSP3.6%ORIC2.8%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
TRVI Trevi Therapeutics, Inc. 15.5% HeldMBX MBX Biosciences, Inc. 12.6% HeldGLUE Monte Rosa Therapeutics, Inc. 11.7% HeldCELC Celcuity Inc. 11.3% Trimmed −25%SGP Spyglass Pharma, Inc. 10.4% HeldSVRA Savara, Inc. 9.5% HeldZBIO Zenas BioPharma, Inc. 6.4% HeldCOUR Coursera, Inc. 4.6% HeldAUPH Aurinia Pharmaceuticals, Inc. 4.2% HeldCRSP Crispr Therapeutics AG 3.6% HeldORIC ORIC Pharmaceuticals, Inc. 2.8% HeldPHAT Phathom Pharmaceuticals, Inc. 1.3% Held
What changed